<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237090</url>
  </required_header>
  <id_info>
    <org_study_id>2020-2110</org_study_id>
    <nct_id>NCT04237090</nct_id>
  </id_info>
  <brief_title>Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel</brief_title>
  <acronym>PREMED-F1</acronym>
  <official_title>Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciusss de L'Est de l'Île de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ciusss de L'Est de l'Île de Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explore the randomized, controlled, double-blind design targeted for the final clinical trial
      to assess the acceptability of interventions and clinical outcome measures and to provide
      data making it possible to estimate the parameters necessary for the preparation,
      modification or even abandonment of the final study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paclitaxel is known to cause 30 to 40% of infusion-related reactions when no premedication is
      administered. It is agreed that all patients should receive premedication with dexamethasone,
      an H1 antagonist, such as diphenhydramine, and an H2 antagonist before the administration of
      paclitaxel. There are several cases where undesirable effects (eg. drowsiness, dry mouth,
      motor impatience) have been reported following the administration of this conventional
      premedication. Diphenhydramine is often accused because of its pharmacological properties.

      A definitive, randomized, double-blind, non-inferiority study can assess whether cetirizine,
      a non-sedating H1 antagonist, can be used as an effective and safe alternative to
      diphenhydramine in the prevention of paclitaxel infusion-related reactions.

      In the current proposed feasibility study, patients will be followed for the first two doses
      of paclitaxel. The goal is to explore the randomized, controlled, double-blind design
      targeted for the final clinical trial to assess the acceptability of interventions and
      clinical outcome measures and to provide data making it possible to estimate the parameters
      necessary for the preparation, modification or even abandonment of the final study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline of drowsiness on Stanford Sleepiness Scale 1 hour after the administration of diphenhydramine</measure>
    <time_frame>15 minutes before the administration of diphenhydramine. 1 hour after the administration of diphenhydramine.</time_frame>
    <description>For treatment 1 and treatment 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline of drowsiness on Stanford Sleepiness Scale upon arrival at home</measure>
    <time_frame>15 minutes before the administration of diphenhydramine. Upon arrival at home.</time_frame>
    <description>For treatment 1 and treatment 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline of drowsiness on Stanford Sleepiness Scale the morning after the administration of diphenhydramine</measure>
    <time_frame>15 minutes before the administration of diphenhydramine. Morning of day 2.</time_frame>
    <description>For treatment 1 and treatment 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recruitment rate accomplished to recruit 24 participants for which a first dose of paclitaxel was administered between February and September 2020.</measure>
    <time_frame>Through study completion, 8 months</time_frame>
    <description>Number of participants per month recruited for which a first dose of paclitaxel was administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants recruited, randomized and having received the first treatment of paclitaxel planned in the study between February and September 2020 following an assessment of their eligibility.</measure>
    <time_frame>Through study completion, 8 months</time_frame>
    <description>Number of participants recruited, randomized and having received the first treatment of paclitaxel planned in the study divided by the number of participants eligible to participate in the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants per group who required stopping the infusion and/or using rescue medication.</measure>
    <time_frame>Day 1</time_frame>
    <description>Stopping the infusion and using rescue medication defined by the medical choice of the attending physician. For treatment 1 and treatment 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion-related reactions grade according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 classification</measure>
    <time_frame>Day 1</time_frame>
    <description>Grades will be determined using nurses notes. For treatment 1 and treatment 2</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of participants who completed the study</measure>
    <time_frame>Through the course of the study, 8 months</time_frame>
    <description>Number of participants who will have completed the study in each group divided by the number of participants recruited in each group</description>
  </other_outcome>
  <other_outcome>
    <measure>Reasons of loss to follow-up using a home-made questionnaire</measure>
    <time_frame>Day 1</time_frame>
    <description>For treatment 1 and treatment 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Maintenance of the blind in participants using a home-made questionnaire</measure>
    <time_frame>Day 1</time_frame>
    <description>At the end of paclitaxel infusion of treatment 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Maintenance of the blind in nurses using a home-made questionnaire</measure>
    <time_frame>Day 1</time_frame>
    <description>At the end of paclitaxel infusion of treatment 1 and 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Side effects experienced by participants using a home-made questionnaire</measure>
    <time_frame>Day 2</time_frame>
    <description>Focus on drowsiness, dry mouth, eyes or nose, dizziness and restlessness/excitement. For treatment 1 and treatment 2.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Oesophageal Cancer</condition>
  <condition>Head Cancer Neck</condition>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Diphenhydramine + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diphenhydramine 50 mg intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion.
Lactose tablet 100 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetirizine + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetirizine tablet 10 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water.
1 milliliter of sodium chloride 0,9 percent intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Drug identification number : 02369567</description>
    <arm_group_label>Diphenhydramine + placebo</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine</intervention_name>
    <description>Drug identification number : 02231603</description>
    <arm_group_label>Cetirizine + placebo</arm_group_label>
    <other_name>Reactine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose pill</intervention_name>
    <description>Natural product number : 00501190</description>
    <arm_group_label>Diphenhydramine + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride 0.9%</intervention_name>
    <description>Drug identification number : 00037796</description>
    <arm_group_label>Cetirizine + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receiving intravenous chemotherapy treatments at the Maisonneuve-Rosemont hospital
             outpatient oncology clinic

          -  Starting their first lifetime treatment with paclitaxel (alone or in combination with
             other anticancer agents).

          -  Capable of giving free and informed consent and who agrees to participate by signing
             the consent form

          -  Aged 18 and over

          -  Able to complete questionnaires

        Exclusion Criteria:

          -  Does not understand French or English

          -  Taking chronic H1 antagonist orally

          -  Taking chronic systemic corticosteroids

          -  Contraindication or possible medical danger, such as a documented allergy or previous
             intolerance, related to the administration of cetirizine, diphenhydramine, placebo or
             any ingredient in their formulation

          -  Has received paclitaxel, docetaxel or paclitaxel nanoparticles linked to albumin in
             the past

          -  Receiving paclitaxel nanoparticles linked to albumin

          -  Severe renal impairment (Cockcroft-Gault &lt;10 milliliters/minute)

          -  Pregnant or breastfeeding women

          -  Receiving paclitaxel under desensitization protocol

          -  Documented or reported dysphagia or other pathophysiological condition preventing a
             tablet from being swallowed whole

          -  Interactions preventing the full dose of oral cetirizine from being absorbed

          -  Participating in another clinical trial simultaneously
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu Picard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ciusss de L'Est de l'Île de Montréal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthieu Picard, M.D.</last_name>
    <phone>1-514-252-3400</phone>
    <phone_ext>5021</phone_ext>
    <email>mpicard.hmr@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe Bouchard, B.Pharm.</last_name>
    <phone>1-514-252-4300</phone>
    <phone_ext>1602</phone_ext>
    <email>pbouchard1.hmr@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIUSSS de l'Est-de-l'île-de-Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu Picard, MD</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>5021</phone_ext>
      <email>mpicard.hmr@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol. 1990 Jul;8(7):1263-8.</citation>
    <PMID>1972736</PMID>
  </reference>
  <reference>
    <citation>Picard M, Castells MC. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review. Clin Rev Allergy Immunol. 2015 Oct;49(2):177-91. doi: 10.1007/s12016-014-8416-0. Review.</citation>
    <PMID>24740483</PMID>
  </reference>
  <reference>
    <citation>Picard M. Management of Hypersensitivity Reactions to Taxanes. Immunol Allergy Clin North Am. 2017 Nov;37(4):679-693. doi: 10.1016/j.iac.2017.07.004. Epub 2017 Aug 18. Review.</citation>
    <PMID>28965634</PMID>
  </reference>
  <reference>
    <citation>Durham CG, Thotakura D, Sager L, Foster J, Herrington JD. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions. J Oncol Pharm Pract. 2019 Sep;25(6):1396-1401. doi: 10.1177/1078155218811505. Epub 2018 Nov 12.</citation>
    <PMID>30419768</PMID>
  </reference>
  <reference>
    <citation>Siderov J, Wendel N, Davis ID. Non-Sedating Antihistamines for Premedication in Ambulatory Oncology Patients. Journal of Pharmacy Practice and Research 2002; 32(2): 108-9.</citation>
  </reference>
  <reference>
    <citation>del Cuvillo A, Mullol J, Bartra J, Dávila I, Jáuregui I, Montoro J, Sastre J, Valero AL. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:3-12. Review.</citation>
    <PMID>17357372</PMID>
  </reference>
  <reference>
    <citation>Banerji A, Long AA, Camargo CA Jr. Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature review. Allergy Asthma Proc. 2007 Jul-Aug;28(4):418-26. Review.</citation>
    <PMID>17883909</PMID>
  </reference>
  <reference>
    <citation>Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer. 2015 Jul;23(7):2019-24. doi: 10.1007/s00520-014-2556-x. Epub 2014 Dec 18.</citation>
    <PMID>25519756</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ciusss de L'Est de l'Île de Montréal</investigator_affiliation>
    <investigator_full_name>Matthieu Picard</investigator_full_name>
    <investigator_title>Assitant clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

